查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1980537

mRNA疗法市场规模、份额、成长及全球产业分析：按类型、应用和地区分類的洞察，2026-2034年预测

mRNA Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 151 Pages | 商品交期: 请询问到货日

价格

mRNA疗法市场的成长要素

2025年全球mRNA疗法市场规模为60.1亿美元。预计到2026年，该市场将成长至68.5亿美元，到2034年将进一步扩大至260.6亿美元，在预测期（2026-2034年）内，复合年增长率高达18.18%。

预计到2025年，北美将引领全球市场，占据31.47%的市场。这主要得益于强劲的研发投入、有利的监管支持以及基于mRNA的新冠疫苗的早期商业化。

随着mRNA疫苗在新冠疫情期间取得成功，市场正经历快速转型。 Moderna、BioNTech、辉瑞和葛兰素史克等主要企业正积极拓展其研发管线，将目标领域从感染疾病扩展到癌症和罕见遗传疾病等领域。

此外，首个 mRNA 药物（一种非疫苗疗法）预计将于 2027 年上市。仅 mRNA 药物领域预计到 2032 年将达到 20 亿美元，并且预计在 2027 年至 2032 年间将以惊人的 118.7% 的复合年增长率增长。

市场动态

市场驱动因素

mRNA疗法的优势

与传统疫苗和治疗方法相比，基于mRNA的疗法具有多项优势。这些优势包括：

  • 在预防重症方面具有很高的有效性
  • 缩短开发週期
  • 对新病毒株的适应力
  • 安全性能良好
  • 整合到基因组的风险较低

新冠肺炎疫情期间展现出的快速反应能力显着增强了人们对mRNA技术的信心。其在感染疾病、肿瘤和罕见疾病等领域的应用不断拓展，持续推动市场成长。

市场限制因素

与保存和稳定性相关的挑战

儘管市场需求依然强劲，但mRNA疗法需要超低温储存，这给物流带来了挑战。在许多资源匮乏的国家，缺乏完善的低温运输基础设施，限制了其供应。

高昂的製造成本

大规模生产mRNA产品需要复杂的纯化製程和先进的脂质奈米颗粒（LNP）递送系统。这些因素显着增加了生产成本，并限制了生产的规模化。

市场机会

药物传输技术的进步

递送系统的持续创新正在提高mRNA的稳定性和治疗效果。此类技术的例子包括：

  • 脂质奈米颗粒（LNPs）
  • 聚合物奈米粒子
  • 阳离子奈米粒子

这些技术提高了药物递送至细胞的效率。预计这些进展将促进下一代mRNA疗法的商业化，尤其是在肿瘤学和罕见疾病领域。

市场挑战

  • 无论哪个地区，都应采用严格的法规结构。
  • 核准流程的变更
  • 公众舆论和对疫苗接种的犹豫
  • 开发中国家的基础建设限制

应对这些挑战对于实现可持续的长期成长至关重要。

市场趋势

超越疫苗：广泛采用

儘管疫苗仍占据市场主导地位，但mRNA技术正越来越多地应用于个人化癌症治疗和罕见遗传疾病的治疗。目前，约40%的mRNA临床试验处于I期，显示该领域的研发管线正在迅速扩展。

製药公司正在大力投资以 mRNA 为基础的癌症治疗疗法，这凸显了该技术革新精准医疗的潜力。

細項分析

按类型

市场区隔按以下步骤进行：

1. 用于预防（疫苗）

2. 製药

2024年，预防医学领域占据市场主导地位，预计将维持主导地位至2026年。事实上，由于目前已通过核准的mRNA产品仅存在于疫苗类别（COVID-19疫苗和RSV疫苗），预计到2026年，该领域将占100%的市场份额。

然而，从 2027 年开始，受癌症治疗和罕见疾病药物研发管线的推动，製药业预计将呈现最高的成长率。

透过使用

  • 感染疾病（预计到 2024 年将占最大份额，到 2026 年将占 100%）
  • 肿瘤学（成长最快的领域）
  • 其他的

截至 2025 年 1 月，监管部门仅对感染疾病应用核准，这进一步凸显了该领域的优越性。

透过分销管道

  • 医院药局（预计到2024年将占据最大市场份额）
  • 药局和零售药房
  • 其他的

由于特殊的管理要求，医院药房占据了最大的市场份额。预计到2026年，医院和零售药局的市占率将达到63.62%。

区域展望

北美洲

预计北美将引领全球市场，到 2025 年市场规模将达到 18.9 亿美元。美国仍然是主要贡献者，这得益于联邦政府的大力资助和 FDA 的核准，预计到 2026 年市场规模将达到 21.6 亿美元。

欧洲

预计欧洲市场将出现显着成长。德国市场预计到2026年将达到3.7亿美元，而英国市场预计到2026年将达到1.5亿美元。

亚太地区

预计亚太地区将呈现最高的成长率。到2026年：

  • 日本：6.3亿美元
  • 中国：5.8亿美元
  • 印度：2.7亿美元

加大研发投入正在推动该地区的扩张。

世界其他地区

儘管拉丁美洲、中东和非洲在 2024 年的市场份额较小，但随着医疗基础设施的改善，这些地区的市场份额预计将稳步增长。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 概述：mRNA技术的进展
  • mRNA疗法的未来成长前景
  • 主要企业管道分析
  • 併购、收购和合作等主要产业趋势
  • 关税对市场的影响

第五章：2021-2034年全球mRNA治疗药物市场分析、洞察与预测

  • 市场分析、洞察与预测：按类型
    • 预防医学（疫苗）
      • 2019冠状病毒病疫苗
      • 非新冠疫苗
    • 製药
  • 市场分析、洞察与预测：按应用领域划分
    • 肿瘤学
    • 感染疾病
    • 其他的
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 药局和零售药房
    • 其他的
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 世界其他地区

第六章：北美mRNA治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲mRNA治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第八章：亚太地区mRNA治疗药物市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：全球其他地区mRNA治疗药物市场分析、洞察与预测（2021-2034年）

第十章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Moderna Inc.
    • BioNTech
    • Pfizer Inc.
    • CureVac SE
    • GSK plc
    • Sanofi
    • Omega Therapeutics
    • Strand Therapeutics
    • Immunomic Therapeutics
Product Code: FBI113411

Growth Factors of mRNA therapeutics Market

The global mRNA therapeutics market was valued at USD 6.01 billion in 2025. The market is projected to grow to USD 6.85 billion in 2026 and further expand to USD 26.06 billion by 2034, exhibiting a strong CAGR of 18.18% during the forecast period (2026-2034).

North America dominated the global market in 2025, accounting for 31.47% market share, driven by robust R&D investments, favorable regulatory support, and early commercialization of mRNA-based COVID-19 vaccines.

The market has undergone rapid transformation following the success of mRNA vaccines during the COVID-19 pandemic. Leading companies such as Moderna Inc., BioNTech, Pfizer Inc., and GSK plc. are actively expanding their pipelines beyond infectious diseases into oncology and rare genetic disorders.

Additionally, the first mRNA drug (non-vaccine therapeutic) is expected to launch in 2027. The mRNA drugs/medications segment alone is projected to reach USD 2 billion by 2032, growing at an exceptional CAGR of 118.7% between 2027 and 2032.

Market Dynamics

Market Drivers

Advantages of mRNA Therapeutics

mRNA-based therapeutics offer several advantages over conventional vaccines and treatments. These include:

  • High efficacy in preventing severe illness
  • Faster development timelines
  • Adaptability to emerging virus strains
  • Favorable safety profile
  • Lower risk of genomic integration

The rapid response capability demonstrated during the COVID-19 pandemic significantly strengthened confidence in mRNA technology. Growing applications in infectious diseases, oncology, and rare disorders continue to drive market expansion.

Market Restraints

Storage and Stability Challenges

Despite strong demand, mRNA therapeutics require ultra-cold storage conditions, creating logistical challenges. Many low-resource countries lack adequate cold chain infrastructure, limiting widespread adoption.

High Manufacturing Costs

The large-scale production of mRNA products involves complex purification processes and advanced lipid nanoparticle (LNP) delivery systems. These factors significantly increase production costs and limit scalability.

Market Opportunities

Advancements in Drug Delivery Technologies

Ongoing innovations in delivery systems are improving mRNA stability and therapeutic effectiveness. Technologies such as:

  • Lipid nanoparticles (LNPs)
  • Polymeric nanoparticles
  • Cationic nanoparticles

are enhancing intracellular delivery efficiency. These advancements are expected to support commercialization of next-generation mRNA therapies, especially in oncology and rare diseases.

Market Challenges

  • Stringent regulatory frameworks across regions
  • Evolving approval pathways
  • Public perception and vaccine hesitancy
  • Infrastructure limitations in developing economies

Addressing these challenges will be essential for sustained long-term growth.

Market Trends

Growing Adoption Beyond Vaccines

While vaccines dominate the market, mRNA technology is increasingly being used for personalized cancer therapies and rare genetic conditions. Nearly 40% of mRNA clinical trials are currently in Phase I, reflecting a rapidly expanding pipeline.

Pharmaceutical companies are heavily investing in oncology-focused mRNA therapeutics, highlighting the technology's potential to revolutionize precision medicine.

Segmentation Analysis

By Type

The market is segmented into:

1. Prophylactic (Vaccines)

2. Drugs/Medications

The prophylactic segment dominated the market in 2024 and is expected to maintain leadership through 2026. In fact, the segment is projected to account for 100% of the market share in 2026, as approved mRNA products currently exist only in the vaccine category (COVID-19 and RSV vaccines).

However, the drugs/medications segment is projected to grow at the fastest rate post-2027, driven by oncology and rare disease pipelines.

By Application

  • Infectious Diseases (Dominant in 2024 and expected to contribute 100% share in 2026)
  • Oncology (Fastest growing)
  • Others

As of January 2025, regulatory approvals exist only for infectious disease applications, reinforcing this segment's dominance.

By Distribution Channel

  • Hospital Pharmacies (Largest share in 2024)
  • Drug Stores & Retail Pharmacies
  • Others

Hospital pharmacies accounted for the highest share due to professional administration requirements. The hospital & retail pharmacies segment is projected to hold 63.62% market share in 2026.

Regional Outlook

North America

North America generated USD 1.89 billion in 2025 and led the global market. The U.S. remains the dominant contributor and is estimated to reach USD 2.16 billion by 2026, supported by strong federal funding and FDA approvals.

Europe

Europe is projected to witness significant growth. Germany is expected to reach USD 0.37 billion by 2026, while the U.K. market is forecast at USD 0.15 billion in 2026.

Asia Pacific

Asia Pacific is anticipated to grow at the fastest rate. By 2026:

  • Japan: USD 0.63 billion
  • China: USD 0.58 billion
  • India: USD 0.27 billion

Increasing R&D investments are fueling regional expansion.

Rest of the World

Latin America and the Middle East & Africa held smaller shares in 2024 but are expected to grow steadily with improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive with key players including:

  • Moderna Inc.
  • BioNTech
  • Pfizer Inc.
  • CureVac SE
  • GSK plc.
  • Sanofi
  • Omega Therapeutics
  • Strand Therapeutics

These companies focus heavily on R&D, pipeline expansion, and strategic partnerships to strengthen their market presence.

Conclusion

The global mRNA therapeutics market is set for remarkable expansion, increasing from USD 6.01 billion in 2025 to USD 6.85 billion in 2026, and reaching USD 26.06 billion by 2034, growing at a CAGR of 18.18%. North America remains the leading region, supported by strong regulatory backing and innovation ecosystems. While vaccines currently dominate the market, the rapid emergence of mRNA-based drugs for oncology and rare diseases signals the next major growth phase. Overcoming storage, cost, and regulatory challenges will be critical to sustaining this strong upward trajectory through 2034.

Segmentation

By Type

  • Prophylactic (Vaccines)
    • COVID-19 Vaccines
    • Non-COVID-19 Vaccines
  • Drugs/Medications

By Application

  • Oncology
  • Infectious Diseases
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Others

By Region

  • North America (By Type, Application, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Type, Application, Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Advancements in mRNA Technology
  • 4.2. Future Growth Prospects for mRNA Therapeutics
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Impact of Tariff on the Market

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Prophylactic (Vaccines)
      • 5.1.1.1. COVID-19 Vaccines
      • 5.1.1.2. Non-COVID-19 Vaccines
    • 5.1.2. Drugs/Medications
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Oncology
    • 5.2.2. Infectious Diseases
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Drug Stores & Retail Pharmacies
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Prophylactic (Vaccines)
      • 6.1.1.1. COVID-19 Vaccines
      • 6.1.1.2. Non-COVID-19 Vaccines
    • 6.1.2. Drugs/Medications
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Oncology
    • 6.2.2. Infectious Diseases
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Drug Stores & Retail Pharmacies
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Prophylactic (Vaccines)
      • 7.1.1.1. COVID-19 Vaccines
      • 7.1.1.2. Non-COVID-19 Vaccines
    • 7.1.2. Drugs/Medications
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Oncology
    • 7.2.2. Infectious Diseases
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Drug Stores & Retail Pharmacies
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Prophylactic (Vaccines)
      • 8.1.1.1. COVID-19 Vaccines
      • 8.1.1.2. Non-COVID-19 Vaccines
    • 8.1.2. Drugs/Medications
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Oncology
    • 8.2.2. Infectious Diseases
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drug Stores & Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Prophylactic (Vaccines)
      • 9.1.1.1. COVID-19 Vaccines
      • 9.1.1.2. Non-COVID-19 Vaccines
    • 9.1.2. Drugs/Medications
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Oncology
    • 9.2.2. Infectious Diseases
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Drug Stores & Retail Pharmacies
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Pfizer Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. CureVac SE
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. GSK plc
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Sanofi
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Omega Therapeutics
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Strand Therapeutics
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Immunomic Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 3: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 4: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 8: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 13: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 14: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 18: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 23: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 24: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global mRNA Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global mRNA Therapeutics Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global mRNA Therapeutics Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global mRNA Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 8: North America mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 10: North America mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America mRNA Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America mRNA Therapeutics Market Value Share (%), By Country, 2025
  • Figure 14: Europe mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 16: Europe mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 18: Europe mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Rest of the World mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 32: Rest of the World mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Rest of the World mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 34: Rest of the World mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Rest of the World mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Global mRNA Therapeutics Market Share (%), By Company, 2025